Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 70, Issue 9, 2011, Pages 1550-1555

  Marder, Wendy ^a   Khalatbari, Shokoufeh ^a   Myles, James D ^a   Hench, Rita ^a   Yalavarthi, Srilakshmi ^a   Lustig, Susan ^a   Brook, Robert ^a   Kaplan, Mariana J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 17; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RHEUMATOID FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE;

ADULT; ANTIBODY TITER; ARTERY BLOOD FLOW; ARTERY COMPLIANCE; ARTERY DILATATION; ARTICLE; BLOOD VESSEL FUNCTION; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPEREMIA; MALE; MICROVASCULATURE; PREDICTION; PRIORITY JOURNAL; PULSE WAVE; QUANTITATIVE ASSAY; RHEUMATOID ARTHRITIS; SCORING SYSTEM; VASCULAR ENDOTHELIUM;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; BLOOD FLOW VELOCITY; BRACHIAL ARTERY; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INTERLEUKIN-17; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PULSATILE FLOW; RHEUMATOID FACTOR; VASODILATION;

EID: 80051471106     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.148031     Document Type: Article

References (62)

1. Kaplan MJ. Management of cardiovascular disease risk in chronic inflammatory disorders. Nat Rev Rheumatol 2009;5:208-17.
2. Schillinger M. Cardiovascular risk stratification in older patients: role of brain natriuretic peptide, C-reactive protein, and urinary albumin levels. JAMA 2005;293:1667-9. (Pubitemid 40471798)
3. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7.
4. Peters MJ, van Halm VP, Voskuyl AE, et al. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009;61:1571-9.
5. Warrington KJ, Kent PD, Frye RL, et al. Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Res Ther 2005;7:R984-91.
6. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
7. Gonzalez-Juanatey C, Llorca J, Testa A, et al. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine (Baltimore) 2003;82:407-13. (Pubitemid 37445043)
8. Vaudo G, Marchesi S, Gerli R, et al. Endothelial dysfunction in young patients with rheumatoid arthritis and low disease activity. Ann Rheum Dis 2004;63:31-5. (Pubitemid 38064600)
9. Celermajer DS. Noninvasive detection of atherosclerosis. N Engl J Med 1998;339:2014-15. (Pubitemid 29024135)
10. Bergholm R, Leirisalo-Repo M, Vehkavaara S, et al. Impaired responsiveness to NO in newly diagnosed patients with rheumatoid arthritis. Arterioscler Thromb Vasc Biol 2002;22:1637-41.
11. Goodson NJ, Wiles NJ, Lunt M, et al. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 2002;46:2010-19.
12. Hamburg NM, Palmisano J, Larson MG, et al. Relation of brachial and digital measures of vascular function in the community: the Framingham heart study. Hypertension 2011;57:390-6.
13. Harris RA, Nishiyama SK, Wray DW, et al. Ultrasound assessment of flow-mediated dilation. Hypertension 2010;55:1075-85.
14. Aird WC. Mechanisms of endothelial cell heterogeneity in health and disease. Circ Res 2006;98:159-62.
15. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722-32. (Pubitemid 40365093)
16. Sattar N, McCarey DW, Capell H, et al. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957-63. (Pubitemid 37553561)
17. Leipe J, Grunke M, Dechant C, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010;62:2876-85.
18. Feng W, Li W, Liu W, et al. IL-17 induces myocardial fibrosis and enhances RANKL/ OPG and MMP/TIMP signaling in isoproterenol-induced heart failure. Exp Mol Pathol 2009;87:212-18.
19. van Es T, van Puijvelde GH, Ramos OH, et al. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem Biophys Res Commun 2009;388:261-5.
20. Liang J, Zheng Z, Wang M, et al. Myeloperoxidase (MPO) and interleukin-17 (IL-17) plasma levels are increased in patients with acute coronary syndromes. J Int Med Res 2009;37:862-6.
21. Mäki-Petäjä KM, Hall FC, Booth AD, et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 2006;114:1185-92. (Pubitemid 44386483)
22. Van Doornum S, McColl G, Jenkins A, et al. Screening for atherosclerosis in patients with rheumatoid arthritis: comparison of two in vivo tests of vascular function. Arthritis Rheum 2003;48:72-80. (Pubitemid 36091650)
23. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
24. Brook RD, Yalavarthi S, Myles JD, et al. Determinants of vascular function in patients with chronic gout. J Clin Hypertens (Greenwich) 2011;13:178-88.
25. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-65. (Pubitemid 34084631)
26. Brook RD, Brook JR, Urch B, et al. Inhalation of fine particulate air pollution and ozone causes acute arterial vasoconstriction in healthy adults. Circulation 2002;105:1534-6. (Pubitemid 34297626)
27. Rajagopalan S, Somers EC, Brook RD, et al. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 2004;103:3677-83. (Pubitemid 38596281)
28. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-19. (Pubitemid 15018832)
29. Wong JB, Ramey DR, Singh G. Long-term morbidity, mortality, and economics of rheumatoid arthritis. Arthritis Rheum 2001;44:2746-9. (Pubitemid 34016193)
30. Jacobsson LT, Knowler WC, Pillemer S, et al. Rheumatoid arthritis and mortality. A longitudinal study in Pima Indians. Arthritis Rheum 1993;36:1045-53. (Pubitemid 23229280)
31. del Rincón ID, Williams K, Stern MP, et al. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45. (Pubitemid 34016192)
32. Park YB, Ahn CW, Choi HK, et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. Arthritis Rheum 2002;46:1714-19. (Pubitemid 34774501)
33. Kumeda Y, Inaba M, Goto H, et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 2002;46:1489-97. (Pubitemid 34620194)
34. Meune C, Touzé E, Trinquart L, et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2009;48:1309-13.
35. Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003;48:54-8. (Pubitemid 36091647)
36. Gonzalez A, Maradit Kremers H, Crowson CS, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007;56:3583-7. (Pubitemid 350100691)
37. Jacobsson LT, Turesson C, Gülfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-18. (Pubitemid 40995372)
38. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905-12. (Pubitemid 47502736)
39. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004;116:305-11. (Pubitemid 38230289)
40. Sidiropoulos PI, Siakka P, Pagonidis K, et al. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. Scand J Rheumatol 2009;38:6-10.
41. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-15.
42. Birkui PJ, Thomson O, Riggio G. [Tobacco dependence: first risk factor of atherosclerosis. Survey among smokers and non-smokers in group dynamics]. Ann Cardiol Angeiol (Paris) 1988;37:73-81.
43. Aizer J, Karlson EW, Chibnik LB, et al. A controlled comparison of brachial artery flow mediated dilation (FMD) and digital pulse amplitude tonometry (PAT) in the assessment of endothelial function in systemic lupus erythematosus. Lupus 2009;18:235-42.
44. Pepine CJ, Anderson RD, Sharaf BL, et al. Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study. J Am Coll Cardiol 2010;55:2825-32.
45. Pieringer H, Stuby U, Pohanka E, et al. Arterial stiffness in a muscular artery in women with longstanding rheumatoid arthritis compared with healthy controls and patients with traditional cardiovascular risk factors. Rheumatol Int 2010;30:1335-9.
46. van Popele NM, Grobbee DE, Bots ML, et al. Association between arterial stiffness and atherosclerosis: the Rotterdam Study. Stroke 2001;32:454-60. (Pubitemid 32155234)
47. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001;37:1236-41. (Pubitemid 34163575)
48. Rho YH, Chung CP, Oeser A, et al. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2009;61:1580-5.
49. Erbel C, Chen L, Bea F, et al. Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice. J Immunol 2009;183:8167-75.
50. de Boer OJ, van der Meer JJ, Teeling P, et al. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol 2010;220:499-508.
51. Eid RE, Rao DA, Zhou J, et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation 2009;119:1424-32.
52. Patel DN, King CA, Bailey SR, et al. Interleukin-17 stimulates C-reactive protein expression in hepatocytes and smooth muscle cells via p38 MAPK and ERK1/2- dependent NF-kappaB and C/EBPbeta activation. J Biol Chem 2007;282:27229-38. (Pubitemid 47501976)
53. Madhur MS, Lob HE, McCann LA, et al. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 2010;55:500-7.
54. Foster W, Carruthers D, Lip GY, et al. Inflammation and microvascular and macrovascular endothelial dysfunction in rheumatoid arthritis: effect of treatment. J Rheumatol 2010;37:711-16.
55. Wallis SK, Cooney LA, Endres JL, et al. A polymorphism in the interleukin-4 receptor affects the ability of interleukin-4 to regulate Th17 cells: a possible immunoregulatory mechanism for genetic control of the severity of rheumatoid arthritis. Arthritis Res Ther 2011;13:R15.
56. Singh R, Aggarwal A, Misra R. Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy. J Rheumatol 2007;34:2285-90. (Pubitemid 350076892)
57. Paradowska-Gorycka A, Wojtecka-Lukasik E, Trefler J, et al. Association between IL-17F gene polymorphisms and susceptibility to and severity of rheumatoid arthritis (RA). Scand J Immunol 2010;72:134-41.
58. Liang KP, Kremers HM, Crowson CS, et al. Autoantibodies and the risk of cardiovascular events. J Rheumatol 2009;36:2462-9.
59. Gerli R, Bartoloni Bocci E, Sherer Y, et al. Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:724-5. (Pubitemid 351571944)
60. López-Longo FJ, Oliver-Miñarro D, de la Torre I, et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 2009;61:419-24.
61. Kerekes G, Szekanecz Z, Dér H, et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol 2008;35:398- 406.
62. Pereira I, Laurindo I, Burlingame R, et al. Auto-antibodies do not influence development of atherosclerotic plaques in rheumatoid arthritis. Joint Bone Spine 2008;75:416-21.